.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Deloitte
Daiichi Sankyo
Boehringer Ingelheim
Citi
McKesson
Accenture
Teva
McKinsey
Cipla

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Try a Free Trial

« Back to Dashboard

Details for Patent: ➤ Try a Free Trial

Title: Method of forming conductive lines
Abstract:Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.
Inventor(s): Schultz; Robert K. (Shoreview, MN), Schultz; David W. (Falcon Heights, MN)
Assignee: 3M Innovative Properties Company (St. Paul, MN)
Filing Date:Mar 29, 2000
Application Number:09/537,151
Claims:1. A method of preparing a solution aerosol formulation comprising the step of combining a therapeutically effective amount of beclomethasone 17, 21 dipropionate, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof, and ethanol in an amount of 2 to 12 percent by weight to solubilize the beclomethasone 17, 21 dipropionate in the propellant.

2. The method of claim 1, wherein said formulation comprises 0.05 to 0.5% by weight beclomethasone 17, 21 dipropionate.

3. The method of claim 1, wherein said propellant is present in an amount of 88 to 98 percent by weight.

4. The method of claim 1, wherein said formulation comprises 1,1,1,2-tetrafluoroethane as the only propellant.

5. The method of claim 1, wherein said formulation comprises 1,1,1,2,3,3,3-heptafluoropropane as the only propellant.

6. The method of claim 1, wherein said formulation is free of surfactant.

7. The method of claim 1, wherein said formulation consists essentially of a therapeutically effective amount of beclomethasone 17, 21 dipropionate, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof, and an amount of ethanol 2 to 12 percent by weight to solubilize the beclomethasone 17, 21 dipropionate in the propellant.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
QuintilesIMS
Harvard Business School
Queensland Health
Deloitte
McKesson
Argus Health
Healthtrust
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot